Purchase this article with an account.
N. Kojo, A. Mekada, Y. Takihata, E. Sekii, A. Okada, M. Tajika, M. Ohji; Intravitreal Injection of Triamcinolone Acetonide for Central Retinal Vein Occlusion With Macular Edema . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4246.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of intravitreal injection of triamcinolone acetonide (TA) for the treatment of macular edema due to central retinal vein occlusion (CRVO).
Twenty patients (20 eyes) with macular edema due to CRVO who had visual acuity (VA) less than 20/50 were enrolled. TA (4 mg) was injected into the vitreous cavity and the patients were followed for 6 months. The best–corrected visual acuity (BCVA), intraocular pressure (IOP), and complications were assessed at baseline and 1, 3, and 6 months after intravitreal TA injection.
The mean logMAR VA was 1.01±0.45 at baseline and improved significantly to 0.69±0.52 at 1 month (p<0.01) , 0.68±0.46 at 3 months (p<0.01) , and 0.78±0.46 at 6 months (p<0.01). At 6 months, the BCVA improved by 3 or more lines in 11 eyes (55%) and deteriorated by 3 or more lines in 1 eye (5%). The IOP levels increased to 22 mmHg or higher in 9 eyes (45%); however, they were well controlled by medications. Retinal detachment developed in one eye (5%) 9 months postoperatively.
: Injection of TA for the treatment of macular edema due to CRVO seems to improve the BCVA for at least the first 6 months postoperatively after injection.
This PDF is available to Subscribers Only